Our results show that the frequency of EGFR mutations at the initial testing among all patients and those with adenocarcinoma was 32.5% versus 33.3% and 42.2% versus 41.9% for Therascreen versus Cobas, respectively. The gene discussed is EGFR; the disease is adenocarcinoma.